OGN Jan 2025 7.500 put
| Previous close | 0.3800 |
| Open | 0.0500 |
| Bid | 0.0500 |
| Ask | 0.7500 |
| Strike | 7.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0500 - 0.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | 323 |
Business WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11
ZacksAre Options Traders Betting on a Big Move in Organon (OGN) Stock?
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
GlobeNewswireOrganon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. BASEL, Switzerland and LONDON and NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Lt
